The CD31 staining assay of MDA-MB-231/MDA-MB-468 tumor tissues at the end of the administration indicated that Bevacizumab could effectively inhibit tumor angiogenesis compared to the PBS control (Fig. 7a). This evidence concerns the gene PECAM1 and neoplasm.